No announcement yet.

Stem Cell Articles

  • Filter
  • Time
  • Show
Clear All
new posts

    Stem Cell Articles

    I thought that I would put a bunch of stem cell stories together into one topic.,2933,288800,00.html

    Women in Europe could be having boob jobs on their lunch breaks as early as next year, according to a scientific journal.

    A fast-track breast enlargement process is to be rolled out by a Californian biotech company and could be introduced across Europe by next year, the Chemistry and Industry magazine says.

    The procedure, called Celution, takes just over an hour and involves injecting a "super-charged'' fat mixture into breast tissue. Fat is taken from a patient's buttocks or stomach using minor liposuction under local anaesthetic.

    The useful stem cells are separated out and an hour later a dose of stem and regenerative cells is packaged into a cartridge ready for injection. It costs a few thousand dollars and the breasts enlarge over about six months, according to the program's creator Cytori Therapeutics.

    Cytori Therapeutics head of research and development Kai Pinkernel said the company's initial focus will be on reconstructive surgery in breast cancer patients.,00.html
    New Discoveries In Neural Stem Cells Have Implications For The Design Of Brain Therapies
    Main Category: Stem Cell Research News
    Article Date: 10 Jul 2007 - 8:00 PDT

    Scientists have discovered that adult neural stem cells, which exist in the brain throughout life, are not a single, homogeneous group. Instead, they are a diverse group of cells, each capable of giving rise to specific types of neurons. The finding, the team says, significantly shifts the perspective on how these cells could be used to develop cell-based brain therapies.

    The results of their study are reported online in Science Express, and will be published in an upcoming issue of Science.

    Adult neural stem cells give rise to the three major types of brain cells -- astrocytes, oligodendrocytes and neurons. Their role in producing neurons is of particular interest to scientists because neurons orchestrate brain functions -- thought, feeling and movement. If scientists could figure out how to create specific types of new neurons, they potentially could use them to replace damaged cells, such as the dopamine-producing neurons destroyed in Parkinson's disease.

    In recent years, scientists have determined that adult neural stem cells are located primarily in two regions of the brain -- the lining of the brain's fluid-filled cavity, known as the subventricular zone, and a horseshoe shaped area known as the hippocampus. The laboratory of the senior author of the current study, UCSF's Arturo Alvarez-Buylla identified the stem cells in the subventricular zone in 1999 (Cell, June 11, 1999).

    While scientists have known that neural stem cells in the developing brain produce particular types of neurons based on where the stem cells are located in the embryo, studies carried out in cell culture have suggested that adult neural stem cells of the fully formed brain can give rise to many types of brain cells.

    In the current study, conducted in mice, the team set out to explore whether neural stem cells in different locations of the subventricular zone are all the same. They did so using a method they developed to follow the fate of early neonatal and adult neural stem cells in 15 different regions of the subventricular zone. These cells typically produce young neurons that migrate to the olfactory bulb, where they mature into several distinct types of interneurons, neurons that are essential for the sense of smell.

    To the team's surprise, the adult neural stem cells in the various regions of the subventricular zone each gave rise to only very specific subsets of interneurons. Moreover, the stem cells were not susceptible to being re-specified. When they were taken out of their niche and transplanted into another region of the subventricular zone, they continued to produce the same subset of interneurons. Similarly, they retained their specialized production of distinct subtypes of neurons when removed from the animals' brains and exposed to a cocktail of growth factors in a culture dish.
    S. Korean lab to clone drug-sniffing dogs
    Seoul National University signed deal with Korea Customs Service
    Updated: 7:18 a.m. ET July 10, 2007

    SEOUL - A South Korean laboratory that produced the world's first cloned dogs is looking to get into the business of cloning canines, first by cloning drug-sniffing dogs, a lab official said on Tuesday.

    The laboratory at Seoul National University, implicated in a scandal for fabricating data in embryonic stem cell studies, has signed a memorandum of understanding with the Korea Customs Service to clone drug-sniffing dogs, said Kim Min-kyu, the researcher who heads the cloning project for the team.

    "However, this is taking place more on an investigative level, so we aren't going to be making a profit from this deal," Kim said, adding: "We have plans to clone dogs commercially in the future."
    Personalized Stem Cells Created ... for Monkeys
    By Brandon Keim EmailJune 21, 2007 | 8:30:00 AMCategories: Biotechnology, Stem Cell Research

    Esc Researchers have reportedly created individually-tailored embryonic stem cell lines in monkeys. If the findings stand, they could be a large step towards making personal ESCs -- the basis of many proposed stem cell therapies -- for people.

    Personalized embryonic stem cells -- as opposed to ESC lines used in research, which come directly from fertilized embryos -- are created through a process called somatic cell nuclear transfer, or SCNT. In this process, the nucleus of a fertilized egg, or oocyte, is removed and then replaced with the nucleus of a regular cell.

    Ideally, the egg with its new nucleus develops normally, and within a few days forms a cell cluster called a blastocyst from which ESCs are harvested. This has proven difficult in less-complex animals and impossible in primates -- until, perhaps, now.

    Cure for blindness in five years

    By Tom Smithard
    A CURE for blindness using stem cell treatment will be available within five years, Yorkshire scientists have revealed.

    Experts at Sheffield University are planning a £4m project to end the main cause of blindness among old people – age-related macular degeneration (AMD). A quarter of people over 60 in the UK are affected.

    The scientists, together with teams from University College London (UCL) and Moorfields Eye Hospital in London, intend to use embryonic stem cells to repair damaged retinas.

    They predict a trial will start in as little as five years and in 10 years time the hour-long operation will be a routine day-surgery procedure. Patients would notice a change in their vision in two to three weeks.

    The project was launched yesterday with £4m funding from an anonymous private donor in the United States.

    In AMD, cells in the middle of the retina begin to die, causing loss of vision that spreads out from the centre of the visual field.

    The project aims to generate new cells from embryonic stem cells in the laboratory and transplant them into the eyes of patients.

    Stem cells are dormant, but are able to turn into different cell types. Embryonic stem cells, among the most potent, are obtained from early-stage embryos the size of a pinhead.

    Nice articles Dr. Young. I read that adult stem cell therapy is conducted in the Unites States for cancer patients, it is not approved for spinal cord injuries, if this is true, why not Dr. Young? Thank you, manouli.



      Sigh. I think I must have said it a thousand times but nobody listens. I am sorry. Here, it is again for the thousandth and one time. Money. There is no clinical trial funding for spinal cord injury. There is such funding for cancer, diabetes, and other conditions.



        Originally posted by Wise Young

        Sigh. I think I must have said it a thousand times but nobody listens. I am sorry. Here, it is again for the thousandth and one time. Money. There is no clinical trial funding for spinal cord injury. There is such funding for cancer, diabetes, and other conditions.

        Forgive me Dr. Young, yes indeed you are always saying no money, is hard to believe it. I think they are punishing us for pushing for embryonic stem cells so they cut the funds, OR WE ARE HAVING MANY STINGY PEOPLE. I want to see maybe in my church we can have a dinner and the money goes to research. I wish I had a rich and famous friends. I'll see if I can have a garage sale to get some money. Every penny counts.


          Originally posted by Wise Young

          Sigh. I think I must have said it a thousand times but nobody listens. I am sorry. Here, it is again for the thousandth and one time. Money. There is no clinical trial funding for spinal cord injury. There is such funding for cancer, diabetes, and other conditions.


          Isn't that redundant? How can a procedure be safe for one application but not another? The buracracy is rediculous... An Adult stem cell trial for spinal cord injury should atleast be truncated(sp) because there is ample evidence they are safe by the fact that there already being used. What a mess we have as a government!!!!

          And are there no private endevears that want to profit from adult stems cells application to the spinal cord? Do they not believe in the procedure? wouldn't the cost of the trial be worth patent of the procedure? is there no money to be had from sci?


            Originally posted by Wise Young

            Sigh. I think I must have said it a thousand times but nobody listens. I am sorry. Here, it is again for the thousandth and one time. Money. There is no clinical trial funding for spinal cord injury. There is such funding for cancer, diabetes, and other conditions.

            Can small SCI focused ASC trials be conducted in the USA with private funding? It is my understanding that autologous stem cells have far fewer regulatory hurdles to clear, correct?

            Could an existing lab (Darwin Prockop's for instance) be contracted as a GMP lab?

            If we can't get the US Government to approve the CRPA, why couldn't a smaller, less costly trial be conducted?

            Are there even any options in the USA besides passage of the CRPA utilizing ASC's?


              Baxter, Mytogen Test Stem Cells to Repair Hearts (Update2)

              By Rob Waters

              July 12 (Bloomberg) -- Delmar Chase, 74, has had two coronary bypass surgeries, stents inserted into his arteries to prop them open, and a pacemaker to keep his heart beating normally. Still, he gets chest pain when he walks even a block.

              Relief may be on the way. Chase is enrolled in a Baxter International Inc. study, to be completed in 2009, testing if stem cells taken from his bone marrow can strengthen his heart. The trial is one of 50 involving 3,200 patients worldwide conducted by academic researchers and a dozen companies racing to market new treatments for heart disease, the No. 1 U.S. killer.

              In March, Osiris Therapeutics Inc. and Mytogen Inc. showed in separate studies involving 60 patients that stem cells improved the pumping of diseased hearts. Two weeks ago, Baxter said a similar therapy decreased chest-pain in two dozen people, spurring a 4.5 percent stock rise. Further reports may help investors determine if these new therapies will crack the $33 billion-a-year U.S. cardiac-care market.

              ``There's a lot of money to chase and a lot of companies want a piece,'' says Jose Haresco, an analyst with Merriman Curhan Ford & Co. in San Francisco. ``Cardiology is the largest area of health expenditures in the country, bigger than cancer.''

              Most heart therapies prevent cardiovascular damage by lowering blood pressure or cholesterol. No existing treatment can actually reverse heart failure, a condition that weakens cardiac muscle and often follows a heart attack. More than 5 million Americans have the disorder, according to the American Heart Association.

              Only Adult Cells Tested

              The new experiments all use adult stem cells harvested from blood, bone, muscle and fat. Stem cells extracted from embryos may be more effective in rebuilding hearts, researchers have said. American trials use the less controversial adult cells because the U.S. government won't finance research that derives stem cells from embryos.

              The human studies generated criticism from scientists who say it is premature to test stem cells in patients, and that much of the positive data is coming from company-sponsored trials.

              Adult stem cells are gathered from a patient's own organs, purified and grown in the laboratory before being injected back into an individual's heart. In March, closely held Mytogen, based in Phoenix, reported that it used such a technique to treat 12 heart failure patients.

              More Efficient

              Six months after the cells were injected, the participants' hearts were pumping more efficiently, researchers reported at the American College of Cardiology's science meeting. New heart tissue that grew in scarred areas also had the electrical signature of viable cardiac muscle, said the report's author, Nabil Dib, director of clinical cardiovascular cell therapy at the University of California, San Diego.

              In May, Advanced Cell Technology Inc., an embryonic stem cell company based in Alameda, California, agreed to acquire Mytogen for $5 million and to assume $1 million in debt. The acquisition is expected to close later this month, and Advanced Cell said it already has tentative commitments that will cover the $20 million to $25 million needed to finish the research.

              Osiris, based in Baltimore, is developing a treatment technique that promises to be easier for hospitals to use. The company uses cells gathered from unrelated donors and injects them into a patient's vein.

              `Off the Shelf'

              Since as many as 5,000 treatments can be made from one donor, ``the cells can be produced in quantity, in advance, offering the chance for an off-the-shelf product,'' said Marc Penn, director of the Bakken Heart-Brain Institute at the Cleveland Clinic.




                Stem Cell Clinic Publishes First Peer Reviewed Paper on Autism Stem Cell Therapy

                SAN DIEGO--(BUSINESS WIRE)--Jul 12, 2007 - The Institute for Cellular Medicine ( announced today what appears to be the first publication in a peer reviewed journal outlining scientific rationale for the use of stem cells in the treatment of autism.

                "The application of stem cell therapy to autism, a condition affecting approximately 1 in 144 children, offers the possibility of addressing the root cause of this disorder," said Dr. Gang Chen, one of the International Scientific Advisors for the Institute of Cellular Medicine. He continued, "While numerous clinics have used adult stem cells therapeutically for years, none of these clinics make it a priority to publish in the peer reviewed literature the scientific basis for their work and findings. As a result, anecdotal findings and observations which would have great value to academic researchers are largely ignored. We hope to correct this."




                  Improved culture media could advance stem cell research

                  By Phil Taylor

                  12/07/2007 - Medicult, a Danish company best known for supplying products for use in fertility clinics, has developed a protein-free cell culture medium that could cut out problems associated The new product - called SSR - performs as well as current products in growing stem cells, but should avoid variation between growth batches and make stem cell culture more reliable and reproducible.

                  In essence, the key to the SSR formulation developed by Medicult is a fully synthetic replacement for human serum albumin (HSA), which is included in all culture media used to cultivate human stem cells at present.

                  HSA is derived from human serum and fulfils a valuable function in protecting fragile growing cells, but also has disadvantages. For example, it can often harbour trace amounts of growth factors and other elements that can influence the growth of cells, and this can mean that the growth of one batch of cells will differ from another even if carried out under the same conditions. There is no chance that this can occur with Medicult's SSR formulation, according to the firm's CEO, Jesper Funding Andersen.

                  "To the best of our knowledge, there is no HSA-free media available for cultivating stem cells yet," he said in an interview, adding that finding media which provide highly-reproducible results will be critical if stem cells are to emerge from the lab and be used in therapeutic applications.

                  Proof-of-concept studies carried out internally at Medicult have already shown that the medium can keep stem cells viable for at least three months and, critically, that they can be maintained in an undifferentiated state over the period and retain their ability to subsequently differentiate into specialised cell types.

                  Andersen noted that the rate of cell division is a little bit lower than with HSA media, but not to an extent that will affect typical applications in stem cell research.

                  The next stage for Medicult is to get external laboratories to reproduce and hopefully validate the internal proof-of-concept studies, according to Andersen.

                  "Our impression so far is that the performance with this adult stem cell formulation is sufficient for current applications," said Andersen, adding that additional work will now be undertaken to refine the SSR formulation so that it is suitable for embryonic stem cells.

                  While there is intense development of all three major types of stem cell - adult, embryonic and cord blood cells - Andersen believes that embryonic stem cells will play the greatest role, particularly in therapeutic applications.





                    Early clinical trials have also shown initial success in patient treatments for Parkinson’s disease and spinal cord injury. And, the first FDA-approved trial to treat juvenile diabetes in human patients is ready to begin at Harvard Medical School, using adult stem cells. In short, they are the building blocks of life itself.

                    I don't know what clinical trials for spinal cord injury have done. Are they talking about other countries, or we did have clinical stem cell trials here. Do you know any?

                    An Introduction To Adult Stem Cells

                    I'm sure you've already heard about Stem Cells. Maybe you saw a news story or a read a news article or saw the Presidential address. They are the most widely publicized scientific discovery today and with good reason. How about Embryonic Stem Cells? They have created a great deal of controversy and with good reason. The lure of what Embryonic Stem Cells can do for our health has led to ethical issues surrounding such things as embryo harvesting. One thing remains, Stem Cells represent the future of Health and Wellness as we know it. And they are here to stay.

                    So what are they?

                    Stem Cells are master cells, meaning that they can generate many, if not all, of the different tissues of the body. They are with us our entire lives and are released naturally from the bone marrow, but like everything else, the process behind their release slows down with age. When there aren't as many stem cells in the blood stream, the body can't repair and renew itself as it once did. These master cells are still contained in the bone marrow in the millions, just not being released as they should.

                    As this natural release occurs we need to concern ourselves with finding ways to reverse it. The good news is there are 4 things we can do.

                    Exercise - as we already know, regular exercise is vital to good health
                    Proper breathing - deep breathing oxygenates the blood and tissues
                    Good Nutrition - we need nutrients to nourish and water to flush toxins from our cells
                    Stem cell enhancers - a new product category set to become what antioxidants are today

                    Stem Cells are the only known source for rebuilding the body and renewing health by restoring lost or degraded cells. They have already been used to help treat things such as Leukemia, AIDS, Alzheimer's Disease and multiple sclerosis.

                    They have been used to form new cartilage, grow new corneas to restore sight to the blind, as treatments for stroke victims, and several groups are using adult stem cells with patients to repair damage after heart attacks.

                    Early clinical trials have also shown initial success in patient treatments for Parkinson’s disease and spinal cord injury. And, the first FDA-approved trial to treat juvenile diabetes in human patients is ready to begin at Harvard Medical School, using adult stem cells. In short, they are the building blocks of life itself.




                      Originally posted by manouli
                      I don't know what clinical trials for spinal cord injury have done. Are they talking about other countries, or we did have clinical stem cell trials here. Do you know any?
                      It’s just bogus, Matt Canham is against hESCR. He is just using stem cell research for other motives than cures.


                        I agree with Leif, this article is basically a bash of hESC's, consequently promoting ASC's as the panacea for everything.

                        The FDA approved trial successfully treating SCI with ASC's (according to the article) cannot be substantiated with anything other than this writers claims.



                          Thank you guys. It's unreal how they are playing with other people's lives because of their believes, and people do believe them and they won't use embryonic stem cells. For second I thought I did miss the clinical trials.

                          Here we go again, they will never stop saying lies.


                          Adult stem cell research on the other hand has treated 73 medical cases which have generated success.

                          Coincidently, Parkinson’s disease, spinal cord injuries, and stroke damages as well as type J juvenile diabetes are listed among these successful treatments.

                          Embryonic stem cell research cases yield no success
                          By Hannah Flanders, Muscatine, Iowa

                          Last edited by manouli; 12 Jul 2007, 11:29 PM.



                            Thanks for posting stories like these dr. young! I copy paste them and send them to interested long standing spinal cord injured friends. I have about 12 friends on my email list and most all are 20 years post injury. I think it shows that no matter how long we have been hurt we still hold the hope of any kind of recovery. The day is coming for old injuries to be included in inovative treatments too. keep the great articles coming.


                              Jefferson City
                              First Stem Cell Reports Show Two Projects

                              July 8, 2007--Posted at 12:45 pm CDT

                              JEFFERSON CITY - The first reports required by a new constitutional amendment show just two human embryonic stem cell research projects in Missouri. Voters passed Amendment Two last year.

                              It guarantees that all federally allowed stem cell research can occur in Missouri. It also requires institutions to make public reports by the end of June about any human stem cell research conducted in the previous calendar year.